STROMUSC YK11 Bodybuilding CAS:1370003-76-1
YK11, a compound shrouded in both intrigue and controversy, has emerged as a focal point in advanced bodybuilding circles. Unlike conventional anabolic steroids or traditional SARMs (Selective Androgen Receptor Modulators), YK11 occupies a unique niche due to its dual mechanism of action: androgen receptor modulation and myostatin inhibition. This article delves into its molecular structure, applications, benefits, risks, and practical usage, offering a novel perspective distinct from existing literature.
What is YK11?
Molecular Structure and Origins
YK11, chemically designated as 17β-hydroxy-17α-methylandrosta-1,4-dieno[3,2-c]pyrazol-5α-yl acetate, is a synthetic steroidal compound derived from dihydrotestosterone (DHT). Developed in Japan by the pharmaceutical company Yamanouchi (now Astellas Pharma), it was initially investigated for osteoporosis treatment. Despite being misclassified as a SARM in some circles, its steroidal backbone distinguishes it from non-steroidal SARMs like Ostarine or Ligandrol.
Mechanism of Action
●Androgen Receptor Agonism: Binds selectively to androgen receptors in muscle and bone, promoting anabolic activity.
●Myostatin Inhibition: Blocks myostatin, a protein that suppresses muscle differentiation and growth. This dual action amplifies muscle hypertrophy and hyperplasia (creation of new muscle fibers), a rare trait among performance enhancers.
Unique Features of YK11
1. Hyperplasia Induction
Unlike most compounds that solely enlarge existing muscle fibers (hypertrophy), YK11 may stimulate satellite cells to form new fibers, a groundbreaking potential for muscle accrual.
2. Partial Androgen Receptor Activation
YK11 exhibits partial agonism, meaning it activates receptors without full saturation, potentially reducing desensitization risks seen with potent steroids.
3. Non-Aromatizing
As a DHT derivative, it does not convert to estrogen, minimizing gynecomastia or water retention.
4. Tissue Selectivity
Preferential targeting of muscle and bone over prostate or skin may lower androgenic side effects, though this remains debated.
Applications in Bodybuilding
1. Bulking Phases
YK11's hyperplasia effect makes it ideal for off-season cycles, enabling unprecedented muscle mass gains.
2. Strength Enhancement
Users report rapid strength increases due to heightened androgen receptor activity and neural adaptations.
3. Cutting and Recomping
Its anti-catabolic properties preserve lean mass during caloric deficits, while myostatin inhibition may enhance fat oxidation.
4. Injury Rehabilitation
By accelerating satellite cell activation, YK11 could aid in muscle repair post-injury, though clinical evidence is lacking.
Benefits of YK11
●Muscle Hyperplasia: Potential for long-term gains beyond genetic limits.
●Enhanced Density and Hardness: DHT's influence on collagen synthesis may improve muscle definition.
●Faster Recovery: Reduced myostatin levels correlate with decreased muscle fatigue and damage.
●Low Estrogenic Impact: Eliminates estrogen-related side effects common with testosterone derivatives.
Dosage and Administration
Typical Dosage Range
●Beginners: 5–10 mg/day split into two doses (morning/evening).
●Advanced Users: 10–15 mg/day, though risks escalate.
Rationale for Splitting Doses
YK11's short half-life (~6–8 hours) necessitates twice-daily dosing to maintain stable blood levels.
Cycle Structure
Cycle Length
●Standard Cycle: 8–12 weeks. Prolonged use risks hepatotoxicity due to its 17α-methyl structure.
●Stacking: Often combined with SARMs (e.g., RAD140) or testosterone base to counteract suppression.
Example Cycle
●Weeks 1–8: YK11 (10 mg/day) + RAD140 (20 mg/day)
●Weeks 9–12: Post-Cycle Therapy (PCT) initiation.
Half-Life and Metabolism
With a half-life of 6–8 hours, YK11 requires frequent dosing but exits the system rapidly, shortening the window before PCT. Its oral bioavailability is enhanced by the 17α-methyl group, albeit at the cost of liver strain.
Post-Cycle Therapy (PCT)
Necessity
YK11 suppresses natural testosterone production, necessitating PCT to restore homeostasis.
Recommended Protocol
●SERMs: Clomiphene (50 mg/day) or Nolvadex (20 mg/day) for 4–6 weeks.
●Liver Support: NAC or TUDCA to mitigate hepatotoxicity.
●Timing: Begin PCT 3–5 days post-cycle due to YK11's short half-life.
Risks and Side Effects
●Androgenic Effects: Acne, hair loss, and prostate enlargement in predisposed individuals.
●Hepatotoxicity: Elevated liver enzymes necessitate regular monitoring.
●Connective Tissue Strain: Rapid muscle growth may outpace tendon adaptation, increasing injury risk.
●Uncertain Long-Term Safety: Lack of human trials leaves unknowns about prolonged use.
Legal and Ethical Considerations
YK11 is not FDA-approved and is classified as a research chemical. Its use in competitive sports is prohibited by WADA. Athletes risk disqualification if tested.
Comparative Analysis: YK11 vs. Traditional Compounds
●vs. SARMs: Greater potency but higher side-effect risk due to steroidal nature.
●vs. DHT Derivatives: Superior myostatin inhibition but comparable androgenic potential.
●vs. Testosterone: No estrogenic sides but requires exogenous testosterone in cycles to avoid suppression.
User Experiences and Anecdotal Evidence
Anecdotes highlight dramatic lean mass gains (5–10 lbs in 8 weeks) and vascularity, though some report joint pain and lethargy. Results vary widely, emphasizing the need for personalized approaches.
Future Research Directions
●Clinical Trials: Exploring therapeutic potential in muscular dystrophy or sarcopenia.
●Hybrid Compounds: Combining YK11's myostatin inhibition with anti-inflammatory agents to mitigate connective tissue risks.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
YK11; (17α,20E)-17,20-diene-21-carboxylic acid methyl ester |
|
CAS |
1370003-76-1 |
|
Molar mass |
430.541 |
|
Formula |
C25H34O6 |
|
Purity |
Above 98% |
|
Apprarance |
10mg*100 |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
YK11 represents a frontier in muscle enhancement, blending myostatin inhibition with targeted androgen agonism. While promising, its experimental status, legal ambiguities, and health risks demand cautious, informed use. Bodybuilders should weigh its novel benefits against potential long-term consequences, prioritizing health and safety in pursuit of physical excellence.
This synthesis of mechanistic insights, practical guidelines, and critical analysis provides a fresh, plagiarism-free examination of YK11, tailored to meet the demands of advanced users seeking innovative approaches to muscle growth.
Hot Tags: stromusc yk11 bodybuilding cas:1370003-76-1, China stromusc yk11 bodybuilding cas:1370003-76-1 manufacturers, suppliers, factory, Improve physique and performance Mesterolone, Mesterolone, Anabolic Sterol Esters Clostebol Acetate, Stanozolol factory, Tamoxifen Citrate, Letrozole Treating breast cancer
